ANTX.US AN2 Therapeutics Inc

Healthcare Biotechnology USA Stocks
4.45 USD
Close of Nov 13, 2026
1.00 7.19
Market cap
USD 169M
P/E
-
P/B
2.23x
ROE
-46.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ANTX.US undervalued?

Graham number

The Graham number of AN2 Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AN2 Therapeutics Inc fundamental analysis

No fundamental analysis for AN2 Therapeutics Inc yet.

AN2 Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AN2 Therapeutics Inc

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the trea…

Full company profile